Is there a role for subcutaneous furosemide in the community and hospice management of end-stage heart failure?

Palliative Medicine

Volumn 25, Issue 6, 2011, Pages 658-663

  Zacharias, Hannah ^a   Raw, Janet ^b   Nunn, Anne ^a   Parsons, Sharon ^b   Johnson, Miriam ^c,d  

^a Yorkshire and Humber Deanery ^*  (United Kingdom)

^b North Yorkshire and York Primary Care Trust   (United Kingdom)

^c UNIVERSITY OF HULL   (United Kingdom)

^d St Catherine's Hospice   (United Kingdom)

Author keywords

Cardiac; furosemide; heart failure; infusions; oedema; palliative care; subcutaneous

Indexed keywords

ANTIBIOTIC AGENT; FUROSEMIDE;

CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG EFFICACY; DYING; FEMALE; FLUID BALANCE; HEART FAILURE; HOSPICE CARE; HOSPITAL ADMISSION; HUMAN; INJECTION SITE REACTION; MALE; RETROSPECTIVE STUDY; REVIEW; SYMPTOM; WEIGHT REDUCTION;

ADULT; CHRONIC DISEASE; DISEASE MANAGEMENT; DIURETICS; FEMALE; FUROSEMIDE; HEART FAILURE; HOSPICE CARE; HUMANS; MALE; PATIENT READMISSION; RESIDENCE CHARACTERISTICS; RETROSPECTIVE STUDIES; TERMINAL CARE;

EID: 80051959101     PISSN: 02692163     EISSN: 1477030X     Source Type: Journal    
DOI: 10.1177/0269216311399490     Document Type: Review

References (25)

1. British Heart Foundation. Projected number of hospital admissions for heart failure in those aged 45 and over, by sex and age, 2006/07- 2026/27. 2010.
2. Cowie MR, Wood DA, Coats AJ, Thompson SG, Suresh V, Poole-Wilson PA, et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart. 2000 ; 83: 505-510 (Pubitemid 30316712)
3. Davidson PM, Cockburn J, Newton PJ. Unmet needs following hospitalization with heart failure: implications for clinical assessment and program planning. J Cardiovasc Nurs. 2008 ; 23: 541-546
4. Murray SA, Boyd K, Kendall M, Worth A, Benton TF, Clausen H. Dying of lung cancer or cardiac failure: prospective qualitative interview study of patients and their carers in the community. Br Med J. 2002 ; 325: 929-929
5. Rogers A, Addington-Hall JM, McCoy AS, Edmonds PM, Abery AJ, Coats AJ, et al. A qualitative study of chronic heart failure patients' understanding of their symptoms and drug therapy. Eur J Heart Fail. 2002 ; 4: 283-287 (Pubitemid 35190352)
6. Rogers AE, Addington-Hall JM, Abery AJ, McCoy AS, Bulpitt C, Coats AJ, et al. Knowledge and communication difficulties for patients with chronic heart failure: qualitative study. Br Med J. 2000 ; 321: 605-607
7. End of Life Care Strategy - promoting high quality care for all adults at the end of life. London: Department of Health, 2010. http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-086277 (accessed 15 February 2011).
8. Beattie JM. The burden of advanced heart failure: an instrument to facilitate population based needs assessment for the provision of palliative/supportive care for management of this chronic progressive disease. London: National Health Services, 2005.
9. Cleland JG, Erhardt L, Murray G, Hall AS, Ball SG. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE study investigators. Eur Heart J. 1997 ; 18: 41-51 (Pubitemid 27105770)
10. Agar M, Currow DC, Shelby-James TM, Plummer J, Sanderson C, Abernethy AP. Preference for place of care and place of death in palliative care: are these different questions?. Palliat Med. 2008 ; 22: 787-795
11. Murray SA, Kendall M, Boyd K, Sheikh A. Illness trajectories and palliative care. Br Med J. 2005 ; 330: 1007-1011 (Pubitemid 40604286)
12. Johnson M, Parsons S, Raw J, Williams A, Daley A. Achieving preferred place of death-is it possible for patients with chronic heart failure?. Br J Cardiol. 2009 ; 16: 194-196
13. Goenaga MA, Millet M, Sanchez E, Garde C, Carrera JA, Arzellus E. Subcutaneous furosemide. Ann Pharmacother. 2004 ; 38: 1751-1751
14. Verma AK, da Silva JH, Kuhl DR. Diuretic effects of subcutaneous furosemide in human volunteers: a randomized pilot study. Ann Pharmacother. 2004 ; 38: 544-549 (Pubitemid 38404274)
15. Brater DC. Resistance to loop diuretics. Why it happens and what to do about it. Drugs. 1985 ; 30: 427-443 (Pubitemid 15240939)
16. van Meyel JJ, Smits P, Dormans T, Gerlag PG, Russel FG, Gribnau FW. Continuous infusion of furosemide in the treatment of patients with congestive heart failure and diuretic resistance. J Intern Med. 1994 ; 235: 329-334 (Pubitemid 24210843)
17. Salvador DR, Punzalan FE and Ramos GC. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 2005; Issue 3: Art. No.: CD003178. DOI: 10.1002/14651858.CD003178.pub3.
18. Thomson MR, Nappi JM, Dunn SP, Hollis IB, Rodgers JE, Van Bakel AB. Continuous versus intermittent infusion of furosemide in acute decompensated heart failure. J Card Fail. 2010 ; 16: 188-193
19. Allen LA, Turer AT, Dewald T, Stough WG, Cotter G, O'Connor CM. Continuous versus bolus dosing of Furosemide for patients hospitalized for heart failure. Am J Cardiol. 2010 ; 105: 1794-1797
20. Ryder M, Murphy NF, McCaffrey D, O'Loughlin C, Ledwidge M, McDonald K. Outpatient intravenous diuretic therapy; potential for marked reduction in hospitalisations for acute decompensated heart failure. Eur J Heart Fail. 2008 ; 10: 267-272
21. Campbell C, Harper A, Elliker M. Introducing 'Palcall': an innovative out-of-hours telephone service led by hospice nurses. Int J Palliat Nurs. 2005 ; 11: 586-590
22. Blue L, Lang E, McMurray JJ, Davie AP, McDonagh TA, Murdoch DR, et al. Randomised controlled trial of specialist nurse intervention in heart failure. Br Med J. 2001 ; 323: 715-718 (Pubitemid 32929432)
23. Heart failure nurse services in England: executive summary. London: British Heart Foundation, 2008.
24. Lichter I, Hunt E. Drug combinations in syringe drivers. N Z Med J. 1995 ; 108: 224-226
25. Morgan S, Evans N. A small observational study of the longevity of syringe driver sites in palliative care. Int J Palliat Nurs. 2004 ; 10: 405-412